SPECIAL NOTICE
A -- Non-Invasive Bio-Sensors for the Detection of Biological Pathogens
- Notice Date
- 11/5/2014
- Notice Type
- Special Notice
- NAICS
- 541711
— Research and Development in Biotechnology
- Contracting Office
- Department of Energy, Sandia Corp. (DOE Contractor), Sandia National Laboratories, PO Box 5800, MS: 0115, Albuquerque, New Mexico, 87185
- ZIP Code
- 87185
- Solicitation Number
- 15_428
- Archive Date
- 12/20/2014
- Point of Contact
- Ron Manginell,
- E-Mail Address
-
rpmangi@sandia.gov
(rpmangi@sandia.gov)
- Small Business Set-Aside
- N/A
- Description
- Sandia National Laboratories has technologies that use non-invasive chemical analysis to potentially detect biological (bacterial and viral) compounds through the use of a small format, point of use instrument utilizing non-invasive chemical analysis. Sandia is conducting ongoing research and development in chemical biomarkers associated with human and animal diseases of interest. This research will establish the feasibility of using non-invasive, portable, rapid screen technology for the detection of infections, such as Ebola and MERS. Sandia's capabilities include revolutionary technologies for the development of portable chemical sensing technologies and chemometrics analysis. Timely development of these technologies may enable their application as a high-volume screen to detect emerging threats to public health. Such a technology could also allow for the development of revolutionary new human and animal diagnostic tests for disease. Sandia currently has a unique opportunity with National Institutes of Health (NIH) to test these technologies in controlled biological settings that could expedite bringing these technologies to market. CRADA or WFO funding from partners would further enable the development of these capabilities with NIH, and place our partners in an excellent position to commercialize the resulting technologies. Sandia seeks to partner with a company or companies interested in opportunities in (a) port of entry diagnosis of human medical conditions and (b) field, clinical or point of use settings. Partnerships may take the form of Cooperative Research & Development Agreements (CRADA), or Work for Others (WFO) agreements. Interested companies are preferred but not required to have experience and expertise in one or more of the following areas: •Development of biomarkers; •FDA medical device approval processes; •Device development; and •Biological/chemical sensors Potential partners must have a significant interest in developing this technology since the CRADA or WFO is expected to include funds-in to Sandia from the partner. CRADAs and WFOs provide the potential for significant competitive advantages for our partners, including up to exclusive licenses to Sandia technologies. To express interest and to obtain information, please contact Ron Manginell via email at rpmangi@sandia.gov. Sandia National Laboratories is a multi-program laboratory managed and operated by Sandia Corporation, a wholly owned subsidiary of Lockheed Martin Corporation, for the U.S. Department of Energy's National Nuclear Security Administration under contract DE-AC04-94AL85000. SAND2014-19426
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/DOE/SNL/SN/15_428/listing.html)
- Record
- SN03566551-W 20141107/141105234142-0bb7654abb32e7b4ec832c9ce42ea100 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |